David C. Marek - Apr 15, 2022 Form 4 Insider Report for Myovant Sciences Ltd. (MYOV)

Role
Principal Executive Officer, Director
Signature
/s/ Matthew Lang, Attorney-in-fact
Stock symbol
MYOV
Transactions as of
Apr 15, 2022
Transactions value $
$0
Form type
4
Date filed
4/19/2022, 04:46 PM
Previous filing
Jan 21, 2022
Next filing
Apr 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYOV Common Shares Award $0 +135K +39.81% $0.00 473K Apr 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYOV Stock Option (Right to Buy) Award $0 +205K $0.00 205K Apr 15, 2022 Common Shares 205K $11.33 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
F2 1/4 of the common shares underlying this option vest on April 15, 2023, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.